Black Diamond Therapeutics Files 2024 10-K
Ticker: BDTX · Form: 10-K · Filed: Mar 6, 2025 · CIK: 1701541
| Field | Detail |
|---|---|
| Company | Black Diamond Therapeutics, Inc. (BDTX) |
| Form Type | 10-K |
| Filed Date | Mar 6, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, biotech, financials
TL;DR
BDTX filed its 2024 10-K. All eyes on their biotech pipeline.
AI Summary
Black Diamond Therapeutics, Inc. filed its 2024 10-K on March 6, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly Aset Therapeutics, Inc., is focused on biological products. Its principal executive offices are located at One Main Street, 14th Floor, Cambridge, MA.
Why It Matters
This filing provides a comprehensive overview of Black Diamond Therapeutics' financial performance and business operations for the fiscal year 2024, crucial for investors assessing the company's current standing and future prospects.
Risk Assessment
Risk Level: medium — As a biotechnology company, Black Diamond Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2024 — Fiscal Year (Reporting period for the 10-K)
- 2023 — Prior Fiscal Year (For comparative financial analysis)
- 2022 — Prior Fiscal Year (For comparative financial analysis)
Key Players & Entities
- Black Diamond Therapeutics, Inc. (company) — Filer of the 10-K
- Aset Therapeutics, Inc. (company) — Former name of Black Diamond Therapeutics
- 2024-12-31 (date) — Fiscal year end
- 2025-03-06 (date) — Filing date
- One Main Street, 14th Floor, Cambridge, MA (location) — Business address
FAQ
What is the primary business of Black Diamond Therapeutics, Inc.?
Black Diamond Therapeutics, Inc. is primarily involved in the biological products sector, specifically focusing on biological products (no diagnostic substances).
When did Black Diamond Therapeutics, Inc. change its name?
The company changed its name from Aset Therapeutics, Inc. on March 21, 2017.
What is the SEC file number for Black Diamond Therapeutics, Inc.'s 10-K filing?
The SEC file number is 001-39200.
Where are Black Diamond Therapeutics, Inc.'s principal executive offices located?
Their principal executive offices are located at One Main Street, 14th Floor, Cambridge, MA 02142.
What period does this 10-K filing cover?
This 10-K filing covers the fiscal year ending December 31, 2024.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 6, 2025 regarding Black Diamond Therapeutics, Inc. (BDTX).